vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $13.8M, roughly 1.4× Gossamer Bio, Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -342.3%, a 322.6% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 35.8%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.

CURI vs GOSS — Head-to-Head

Bigger by revenue
CURI
CURI
1.4× larger
CURI
$19.2M
$13.8M
GOSS
Growing faster (revenue YoY)
GOSS
GOSS
+11.3% gap
GOSS
47.1%
35.8%
CURI
Higher net margin
CURI
CURI
322.6% more per $
CURI
-19.7%
-342.3%
GOSS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
GOSS
GOSS
Revenue
$19.2M
$13.8M
Net Profit
$-3.8M
$-47.2M
Gross Margin
Operating Margin
-17.6%
-333.6%
Net Margin
-19.7%
-342.3%
Revenue YoY
35.8%
47.1%
Net Profit YoY
-34.6%
-43.0%
EPS (diluted)
$-0.07
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
GOSS
GOSS
Q4 25
$19.2M
$13.8M
Q3 25
$18.4M
$13.3M
Q2 25
$19.0M
Q1 25
$15.1M
Q4 24
$14.1M
Q3 24
$12.6M
Q2 24
$12.4M
$95.8M
Q1 24
$12.0M
$0
Net Profit
CURI
CURI
GOSS
GOSS
Q4 25
$-3.8M
$-47.2M
Q3 25
$-3.7M
$-48.2M
Q2 25
$784.0K
Q1 25
$319.0K
Q4 24
$-2.8M
Q3 24
$-3.1M
Q2 24
$-2.0M
$49.2M
Q1 24
$-5.0M
$-41.9M
Operating Margin
CURI
CURI
GOSS
GOSS
Q4 25
-17.6%
-333.6%
Q3 25
-24.5%
-369.4%
Q2 25
2.5%
Q1 25
0.5%
Q4 24
-27.4%
Q3 24
-25.8%
Q2 24
-20.6%
54.3%
Q1 24
-30.4%
Net Margin
CURI
CURI
GOSS
GOSS
Q4 25
-19.7%
-342.3%
Q3 25
-20.4%
-362.7%
Q2 25
4.1%
Q1 25
2.1%
Q4 24
-19.9%
Q3 24
-24.3%
Q2 24
-16.4%
51.4%
Q1 24
-42.0%
EPS (diluted)
CURI
CURI
GOSS
GOSS
Q4 25
$-0.07
$-0.21
Q3 25
$-0.06
$-0.21
Q2 25
$0.01
Q1 25
$0.01
Q4 24
$-0.05
Q3 24
$-0.06
Q2 24
$-0.04
$0.22
Q1 24
$-0.09
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
GOSS
GOSS
Cash + ST InvestmentsLiquidity on hand
$27.3M
$136.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$-122.8M
Total Assets
$75.7M
$172.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
GOSS
GOSS
Q4 25
$27.3M
$136.9M
Q3 25
$27.8M
$180.2M
Q2 25
$28.1M
Q1 25
$33.4M
Q4 24
$32.1M
Q3 24
$33.2M
Q2 24
$39.5M
$354.5M
Q1 24
$38.8M
$244.4M
Stockholders' Equity
CURI
CURI
GOSS
GOSS
Q4 25
$41.5M
$-122.8M
Q3 25
$47.2M
$-82.3M
Q2 25
$49.8M
Q1 25
$58.1M
Q4 24
$57.8M
Q3 24
$62.2M
Q2 24
$64.8M
$81.5M
Q1 24
$67.0M
$26.7M
Total Assets
CURI
CURI
GOSS
GOSS
Q4 25
$75.7M
$172.2M
Q3 25
$74.7M
$208.8M
Q2 25
$78.7M
Q1 25
$85.3M
Q4 24
$86.2M
Q3 24
$87.6M
Q2 24
$90.9M
$373.4M
Q1 24
$94.6M
$259.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
GOSS
GOSS
Operating Cash FlowLast quarter
$4.0M
$-48.3M
Free Cash FlowOCF − Capex
$3.9M
FCF MarginFCF / Revenue
20.5%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
GOSS
GOSS
Q4 25
$4.0M
$-48.3M
Q3 25
$4.4M
$-36.2M
Q2 25
$2.8M
Q1 25
$1.9M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$2.2M
$116.3M
Q1 24
$666.0K
$-52.3M
Free Cash Flow
CURI
CURI
GOSS
GOSS
Q4 25
$3.9M
Q3 25
Q2 25
Q1 25
$1.8M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
CURI
CURI
GOSS
GOSS
Q4 25
20.5%
Q3 25
Q2 25
Q1 25
12.2%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
CURI
CURI
GOSS
GOSS
Q4 25
0.1%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
0.0%
Q1 24
0.0%
Cash Conversion
CURI
CURI
GOSS
GOSS
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
2.36×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons